Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …

This review summarises the evidence that chronic low grade inflammation triggers changes
that contribute to the mental and physical ill health of patients with major depression …

Major depressive disorder (MDD) will affect one out of every five people in their lifetime and
is the leading cause of disability worldwide. Nevertheless, mechanisms associated with the …

Objective Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has
shown rapid antidepressant effects, but small study groups and inadequate control …

The number of the elderly across the globe will approximate 2.1 billion by 2050. Juxtaposed
against this burgeoning segment of the population is evidence that nonpathological aging is …

How do people cope with stressful experiences? What makes a coping strategy effective for
a particular individual? This volume comprehensively examines the nature of psychosocial …

Context Existing therapies for major depression have a lag of onset of action of several
weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have …

Increasing evidence demonstrates that neuroplasticity, a fundamental mechanism of
neuronal adaptation, is disrupted in mood disorders and in animal models of stress. Here we …

All available antidepressant medications are based on serendipitous discoveries of the
clinical efficacy of two classes of antidepressants more than 50 years ago. These tricyclic …

The limited success of genetic studies of major depression has raised questions concerning
the definition of genetically relevant phenotypes. This paper presents strategies to improve …